22.02
Ideaya Biosciences Inc stock is traded at $22.02, with a volume of 1.10M.
It is up +0.96% in the last 24 hours and up +1.62% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$21.81
Open:
$22.15
24h Volume:
1.10M
Relative Volume:
0.93
Market Cap:
$1.93B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-10.05
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
+2.75%
1M Performance:
+1.62%
6M Performance:
-4.84%
1Y Performance:
-48.48%
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IDYA
Ideaya Biosciences Inc
|
22.02 | 1.88B | 23.38M | -155.22M | -134.36M | -2.19 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-22-25 | Initiated | TD Cowen | Buy |
Jul-10-25 | Resumed | Goldman | Neutral |
Jun-26-25 | Initiated | Wells Fargo | Overweight |
Nov-18-24 | Initiated | Stephens | Overweight |
Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Oct-24-24 | Initiated | UBS | Buy |
Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
Jul-08-24 | Initiated | Mizuho | Outperform |
Mar-08-24 | Initiated | BTIG Research | Buy |
Aug-08-23 | Initiated | SVB Securities | Outperform |
May-24-23 | Initiated | Goldman | Buy |
Apr-24-23 | Upgrade | Stifel | Hold → Buy |
Mar-23-23 | Initiated | Berenberg | Buy |
Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
Dec-28-22 | Initiated | CapitalOne | Overweight |
Oct-27-22 | Initiated | Citigroup | Buy |
Aug-15-22 | Downgrade | Stifel | Buy → Hold |
Jul-18-22 | Resumed | Oppenheimer | Outperform |
Mar-10-22 | Upgrade | Stifel | Hold → Buy |
Sep-23-21 | Initiated | Stifel | Hold |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
Mar-11-21 | Initiated | Guggenheim | Buy |
Oct-07-20 | Initiated | Wedbush | Outperform |
Sep-01-20 | Initiated | Northland Capital | Outperform |
Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
Apr-06-20 | Initiated | H.C. Wainwright | Buy |
Mar-13-20 | Initiated | ROTH Capital | Buy |
Oct-17-19 | Initiated | Oppenheimer | Outperform |
Sep-10-19 | Initiated | Robert W. Baird | Outperform |
Jun-17-19 | Initiated | Citigroup | Buy |
Jun-17-19 | Initiated | JP Morgan | Neutral |
Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
IDEAYA Biosciences Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com
Is IDEAYA Biosciences Inc. a good long term investmentRobust financial gains - jammulinksnews.com
What drives IDEAYA Biosciences Inc. stock priceOver 200% growth - Autocar Professional
Breakthrough Lung Cancer Drug IDE849 Shows First Human Results: 70+ Patient Data Coming at WCLC 2025 - Stock Titan
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.
What analysts say about IDEAYA Biosciences Inc. stockHigh-return market picks - jammulinksnews.com
IDEAYA Biosciences: TD Cowen initiates coverage with Buy rating. - AInvest
Promising Pipeline and Strategic Focus Drive Buy Rating for IDEAYA Biosciences - TipRanks
TD Cowen initiates Ideaya Biosciences stock with Buy rating By Investing.com - Investing.com Canada
autocarpro> 2025> What analysts say about IDEAYA Biosciences Inc. stockPhenomenal trading returns - Autocar Professional
IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan
(IDYA) Proactive Strategies - news.stocktradersdaily.com
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionROI Driven Alerts - Newser
How IDEAYA Biosciences Inc. stock performs during market volatilityDaily Stock Radar - Newser
Ideaya Biosciences stock gets Neutral rating from Goldman Sachs By Investing.com - Investing.com Canada
Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital - MSN
Ideaya Biosciences shares fall 2.68% intraday as Biocytogen Pharmaceuticals enters into a global licensing agreement with BeOne Medicines. - AInvest
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences stock price target lowered to $30 by RBC Capital - Investing.com Canada
RBC Cuts Price Target on IDEAYA Biosciences to $30 From $57, Keeps Outperform, Speculative Risk - MarketScreener
Here's Why We're Watching IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - 富途牛牛
(IDYA) Long Term Investment Analysis - news.stocktradersdaily.com
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell Small Cap Comp Growth Index - MarketScreener
IDEAYA Biosciences: A Precision Oncology Play Gains Momentum with Russell 2000 Inclusion - AInvest
Why IDEAYA's Russell Exit Could Be a Biotech Contrarian's Dream - AInvest
IDEAYA Biosciences: A CFO's Deal-Making Expertise Could Be the Catalyst for a Breakout Year - AInvest
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
This NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Ideaya Biosciences shareholders elect directors and approve auditor at annual meeting - Investing.com
Rhumbline Advisers Increases Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Holdings Lifted by GAMMA Investing LLC - Defense World
Handelsbanken Fonder AB Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cantor Fitzgerald Comments on IDYA FY2026 Earnings - Defense World
Transcript : IDEAYA Biosciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by California State Teachers Retirement System - Defense World
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events - PR Newswire
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):